

Recent advances in the synthesis and biological activity studies of pyridine and pyrimidine derivatives: A review

Piridin ve pirimidin türevlerinin sentezi ve biyolojik aktivite çalışmalarındaki son gelişmeler: Bir inceleme

Gönül Bükülmez^{1*} , Rahmi Kasımoğulları¹ 

¹Department of Chemistry, Faculty of Arts and Sciences, Kütahya Dumlupınar University, Kütahya, Türkiye.
gonul.bukulmez@dpu.edu.tr, rahmi.kasimogullari@dpu.edu.tr

Received/Geliş Tarihi: 27.05.2025

Revision/Düzeltilme Tarihi: 10.09.2025

doi: 10.65206/pajes.68353

Accepted/Kabul Tarihi: 21.10.2025

Review Article/Derleme Makalesi

Abstract

Pyridine and pyrimidine derivatives are aromatic heterocyclic compounds containing one or more nitrogen atoms and have a wide range of applications in modern drug design and development. Their ability to interact at the molecular level, pharmacophore properties, and bioavailability potential make them highly suitable candidates for various therapeutic targets. These derivatives, which can exhibit pharmacological effects such as antibacterial, antifungal, antiviral, anticancer, and anti-inflammatory, play a critical role in the development of molecules with multiple mechanisms of action. Recent studies show that these heterocyclic skeletons can be optimized by chemical modifications to increase their selectivity and efficacy against biological targets. This review discusses innovative methods for the synthesis of pyridine and pyrimidine derivatives, structural diversity strategies, and biological activities of these compounds in vitro and in vivo. Furthermore, recent scientific advances on the mechanisms of action of these compounds in biological systems are discussed, and perspectives that will contribute to future drug discovery efforts are put forward.

Keywords: Pyridine, Pyrimidine, Heterocyclic, Drugs, Biological Activity.

Öz

Piridin ve pirimidin türevleri, bir veya daha fazla azot atomu içeren aromatik heterosiklik bileşiklerdir ve modern ilaç tasarımı ve geliştirilmesinde geniş bir uygulama alanına sahiptir. Moleküler düzeyde etkileşime girme yetenekleri, farmakofor özellikleri ve biyoyararlanım potansiyelleri, onları çeşitli terapötik hedefler için oldukça uygun adaylar haline getirmektedir. Antibakteriyel, antifungal, antiviral, antikanser ve anti-inflamatuar gibi farmakolojik etkiler gösterebilen bu türevler, çoklu etki mekanizmalarına sahip moleküllerin geliştirilmesinde kritik bir rol oynamaktadır. Son çalışmalar, bu heterosiklik iskeletlerin biyolojik hedeflere karşı seçiciliklerini ve etkinliklerini artırmak için kimyasal modifikasyonlarla optimize edilebileceğini göstermektedir. Bu derlemede, piridin ve pirimidin türevlerinin sentezi için yenilikçi yöntemler, yapısal çeşitlilik stratejileri ve bu bileşiklerin in vitro ve in vivo biyolojik aktiviteleri tartışılmaktadır. Ayrıca, bu bileşiklerin biyolojik sistemlerdeki etki mekanizmalarına ilişkin son bilimsel gelişmeler tartışılmakta ve gelecekteki ilaç keşif çabalarına katkıda bulunacak perspektifler ortaya konmaktadır.

Anahtar kelimeler: Piridin, Pirimidin, Heterosiklik, İlaçlar, Biyolojik Aktivite.

1 Introduction

Heterocyclic compounds are involved in many drug molecules and are used in different therapeutic areas such as antifungal [1]-[4], antiviral [5]-[7], antidepressant [8]-[10], anticancer [11],[12], and anti-inflammatory agents [13],[14]. The biological activity of these structures has made them molecules that play a key role in drug design. That is, in both organic and medicinal chemistry, heterocyclic compounds constitute an important research area for the discovery of new and effective treatment methods [15]-[19]. In this context, another research area of interest in medicinal chemistry is the design and synthesis of metal complexes with pyridine and pyrimidine structures [20]-[23]. In particular, metal complexes containing Schiff bases have been reported to exhibit remarkable thermochromic and photochromic properties [24]. These properties make these complexes valuable in various applications such as imaging systems [25], organic light emitting diodes [26], photonic/electronic devices [27], and solar filters [28]. Moreover, the coordination of metals with different biological ligands plays an important role in understanding biological processes and opens new horizons in explaining the biochemical functions of biometals [29].

Pyridine has a six-membered ring structure consisting of one nitrogen and five carbon atoms and is an important heterocyclic compound in organic chemistry (Figure 1).




Figure 1. Basic ring structures of pyridine and pyrimidine.

The presence of the nitrogen atom in the ring has a marked effect on the chemical and biological properties of pyridine [30]. Pyridine is a widely used building block, especially in drugs with various biological activities such as antimicrobial [31]-[44], antitumor [45]-[49], antiviral [50]-[52], antituberculosis [53],[54], and anti-Alzheimer's [55],[56]. Pyrimidine exhibits a similar structure to pyridine, but has two nitrogen atoms in the first and third positions of its six-membered ring [57]. This difference makes pyrimidine have more biologically specific functions. Pyrimidine derivatives are considered one of the basic building blocks of genetic material, as they are located in DNA and RNA bases (uracil, thymine, and cytosine) [58],[59]. They also form the basic structure of many

drugs with anticancer [60]-[66], antimicrobial [67]-[70], antiviral [71],[72], and anticonvulsant [73] properties. Both ring systems are widely used in drug discovery. Thus, the fact that pyridine and pyrimidine derivatives offer such a broad spectrum of biological activity has made them indispensable structures in pharmaceutical research and the development of new treatment methods [74].

Although many studies in the literature have separately examined the specific biological activities or synthesis methods of these compounds, studies that comprehensively evaluate both their recent synthesis strategies and their versatile biological activities together are limited. In order to address this shortcoming, in our article, both the current synthesis methods and the biological activities of these compounds, such as anticancer, antibacterial, antiviral, and neurotropic, have been systematically reviewed. Thus, our study aims not only to compile the available information in the literature but also to encourage further in-depth exploration of the biological and pharmaceutical potential of nitrogen-containing heterocyclic compounds.

2 Synthesis and biological activity studies of pyridine and pyrimidine derivatives

2.1 Anticancer activity studies

In 2020, Jian et al. synthesized 26 novel pyrazolo[3,4-b]pyridine-linked compounds **1** combretastatin A-4 analogs that exhibited antiproliferative and tubulin polymerization inhibitory activities (Figure 2).




Figure 2. Synthesis of compound 1.

The most active analog, compound **2**, arrests HeLa cells in a dose-dependent manner, indicating the potential for developing potent tubulin inhibitors as anticancer agents (Figure 3). The molecular docking study revealed that this compound likely occupied the colchicine binding site at the α/β -tubulin interface, using similar binding modes as CA-4 [75].




Figure 3. Compound **2**. ($IC_{50} \pm SD$: $18.08 \pm 1.48 \mu M$)

The study by Hatti et al. 2024 focused on the synthesis of 1,3,4-oxadiazole derivatives linked to pyridine and substituted aryl groups. In the first step, nicotinic acid **3** was refluxed with ethanol and a catalytic amount of H_2SO_4 for 6 h to obtain ethyl pyridine-3-carboxylate **4**. The obtained ester was refluxed with a mixture of ethanol and hydrazine hydrate for 6 h to synthesize pyridine-3-carbohydrazide derivative **5**. In the final step, compound **5** was converted into 2,5-disubstituted 1,3,4-oxadiazole derivatives **6** by cyclocondensation with various aromatic carboxylic acids in the presence of polyphosphoric acid (PPA) at 90°C for 4 hours (Figure 4).




Figure 4. Synthesis of compound **6**.

The anticancer activities of the oxadiazole derivatives against HeLa, MDA-MB-231, MCF-7, and A549 cell lines were investigated using doxorubicin as a standard drug, and the MTT reduction assay protocol (Table 1). It is very important that these derivatives did not show any cytotoxicity on HEK-293 kidney cell lines. In particular, the compound with a cinnamyl ring was found to exhibit better activity against HeLa and MCF-7 cell lines [76].

In 2023, Jami et al. synthesized a new series of **7** amide derivatives of isoxazole-imidazo[1,2-a]pyridine derivatives (Figure 5). In order to evaluate their anticancer potential, the effects of these derivatives on prostate cancer cell lines (PC3 and DU-145), lung cancer cell line (A549), and breast cancer cell line (MCF-7) were studied by MTT assay. The *in vitro* anticancer activity of these compounds was compared with that of the clinical drug candidate etoposide. As a result of the study, five compounds exhibited stronger anticancer activity compared to the positive control (Table 2) [77]. These findings suggest that these compounds in particular could be potential drug candidates in cancer treatment.

Table 1. *In vitro* cytotoxicity of the compound showing anticancer activity with IC₅₀ in μ M and the drug doxorubicin.

Compound	Ar	MDA-MB-231	A549	HeLa	MCF-7	HEK 293
	cinnamyl	-	8.9 $\pm$ 0.06	1.8 $\pm$ 0.3	1.3 $\pm$ 0.11	97 $\pm$ 0.8
Doxorubicin	-	0.36 $\pm$ 0.14	0.47 $\pm$ 0.4	0.98 $\pm$ 0.14	0.89 $\pm$ 0.26	-

Table 2. *In vitro* cytotoxicity of five compounds showing potent anticancer activity with IC₅₀ in μ M and the drug etoposide.

Compound	R	PC3	A549	MCF-7	DU-145
	3,4,5-trimethoxy	0.01 $\pm$ 0.009	0.11 $\pm$ 0.066	0.14 $\pm$ 0.074	0.51 $\pm$ 0.096
	3,5-dimethoxy	0.83 $\pm$ 0.093	0.75 $\pm$ 0.081	0.56 $\pm$ 0.098	0.89 $\pm$ 0.055
	4-methoxy	1.37 $\pm$ 0.46	1.44 $\pm$ 0.52	2.01 $\pm$ 0.86	1.93 $\pm$ 2.03
	4-methyl	2.47 $\pm$ 1.73	2.11 $\pm$ 1.64	2.09 $\pm$ 1.40	2.61 $\pm$ 1.55
	4-(dimethylamino)	2.70 $\pm$ 1.62	1.99 $\pm$ 0.75	1.39 $\pm$ 0.66	3.55 $\pm$ 2.22
Etoposide	-	2.39 $\pm$ 1.56	3.08 $\pm$ 0.135	2.11 $\pm$ 0.024	1.97 $\pm$ 0.45




Figure 5. Synthesis of compound 7.

The study on novel pyrrole-pyridine benzamide derivatives **8** synthesized by Zhang et al. in 2022 represents an important step forward, especially in cancer research (Figure 6). The cytotoxic activities of 27 synthesized compounds were tested against non-small cell lung cancer (A549), cervical cancer (HeLa), and breast cancer (MCF-7) cells. Cabozantinib anticancer drug was taken as a positive control in the tests performed using the MTT method. According to the results obtained, the compound containing bromophenyl ring showed better antitumor activity in the rate of inhibition of tumor growth compared to Cabozantinib (Table 3). This finding is promising for the development of potential new drug candidates for the treatment of cancer [78].

The study carried out by Khan et al. in 2023 focused on the synthesis of pyrimidine-based thiazolidinone derivatives **9**. This synthesis was carried out using stepwise processes (Figure 7). The anti-urease and anticancer activities of the obtained compounds were investigated in the presence of standard drugs thiourea, and tetrandrineb. The four compounds tested in the study showed excellent results for both activity profiles (Table 4). These findings are considered

an important development in terms of potential therapeutic applications of the related compounds [79].




Figure 6. Synthesis of compound 8.




Figure 7. Synthesis of compound 9.

The study by Wang et al. in 2021 focused on 2,4-diamino pyrimidine (DAPY) derivatives 10-11 and investigated their potential as focal adhesion kinase (FAK) inhibitors (Figure 8). FAK is an enzyme overexpressed especially in tumor cells, and plays an important role in cancer cell survival, metastasis, and angiogenesis. Therefore, inhibiting FAK is considered a promising approach for cancer therapy.

Table 3. Compound showing potent anticancer activity and IC₅₀ values of Cabozantinib in μM .

Compound	R	R ₁	R ₂	A549	HeLa	MCF-7
	H	F	4-Br	1.06 ± 0.04	10.87 ± 2.15	0.11 ± 0.02
Cabozantinib	-	-	-	0.33 ± 0.05	79.06 ± 0.39	30.87 ± 0.23

Table 4. IC₅₀ values of compounds and standard drugs with anti-urease ($\mu\text{M} \pm \text{SEM}$) and anticancer ($\text{mM} \pm \text{SEM}$) potential.

Compound	Ar	Anti-urease	Anticancer
-	4-CF ₃ -C ₆ H ₄	2.30 ± 0.30	3.20 ± 0.50
-	3-CF ₃ -C ₆ H ₄	3.10 ± 0.20	6.20 ± 0.10
-	4-F-2-OH-C ₆ H ₄	3.20 ± 0.20	3.80 ± 0.30
-	3-Cl-4-F-C ₆ H ₄	4.20 ± 0.20	5.10 ± 0.30
Thiourea	-	8.20 ± 0.20	-
Tetrandrineb	-	-	12.30 ± 0.10




Figure 8. Synthesis of compound 10 and compound 11.

Most of the DAPY derivatives synthesized in the study effectively suppressed the enzymatic activities of FAK *in vitro*. In particular, compounds 2-Cl, and 2-methoxy bonded to the ring showed potent antiproliferative activity against FAK-overexpressing pancreatic cancer cell lines PANC-1, and BxPC-3. These compounds not only slowed down the growth of cancer cells but also suppressed their ability to form colonies, migrate, and invade in a dose-dependent manner. A flow cytometry assay showed that these compounds induced apoptosis in PANC-1 cells and inhibited cell division by arresting the cell cycle in the G2/M phase. These results suggest that 2-Cl and 2-methoxy bonded compounds to the ring are potent FAK inhibitors with both antitumor, and anti-angiogenesis potential (Table 5) [80].

In a study conducted by Reddy et al. in 2024, pyridine, and triazole-containing pyrimidine derivatives **12** were synthesized, and their *in vitro* anticancer activities against various human cancer cell lines were evaluated using the MTT method. MCF-7 (breast cancer), A549 (lung cancer), Colo-205 (colon cancer), and A2780 (ovarian cancer) cell lines were used in the study (Figure 9). The IC₅₀ values obtained revealed that the compounds showed good to moderate anticancer activity compared to etoposide. In particular, six derivatives exhibited stronger activity than the others, of which the compound 3,4,5-(OCH₃)₃ linked to the ring is the most remarkable and showed promising anticancer activity. (Table 6) [81].

2.2 Neurotropic activity studies

The work of Dashyan et al. in 2024 involved the synthesis of novel compounds **13-14** with a wide range of biological

activities, such as neuropeptide antagonists, anticancer, antiulcer, antiarthritic, and antidiabetic effects. Ethyl 4-phenyl-2-thioxo-1,2-dihydropyridine-3-carboxylate derivatives were used in the synthesis of these compounds (Figure 10).




Figure 9. Synthesis of compound 12.




Figure 10. Synthesis of compound 13 and compound 14.

Table 5. Kinase inhibitory activities and antiproliferative activities of compounds with potent antiproliferative activity and defactinib used as standard against different human cell lines.

Enzymatic activity (IC ₅₀ , nM)			Antiproliferative activity (IC ₅₀ /μM)							
		Cancer cells								
Compound	R ₁ /R ₂	FAK	VRGFR2	PANC-1	BxPC-3	MCF-7	MDA- MB-231	HepG2	A549	HCT-15
10	2-Cl-C ₆ H ₄	2.75	146.8	0.98	0.55	1.47	0.76	0.71	2.72	0.79
11	2-OMe-C ₆ H ₄	1.87	291.8	0.11	0.15	0.25	0.35	0.14	0.65	0.12
Defactinib	-	1.16	273.2	3.48	3.25	5.81	3.75	3.69	4.09	4.36
Antiproliferative activity (IC ₅₀ /μM)										
Normal cells										
Compound			R ₁ /R ₂		HUVEC		HEK293		L02	
10			2-Cl-C ₆ H ₄		2.29		4.92		15.14	
11			2-OMe-C ₆ H ₄		0.18		16.17		>20	
Defactinib			-		3.24		4.07		4.66	

Table 6. IC₅₀ values in μM of compounds with strong anticancer activity and Etoposide used as standard.

Compound	R	MCF-7	A549	Colo-205	A2780
-	3,4,5-(OCH ₃) ₃	0.1 ± 0.075	0.26 ± 0.037	0.48 ± 0.048	0.13 ± 0.023
-	3,5-(OCH ₃) ₂	0.86 ± 0.064	0.94 ± 0.082	1.49 ± 0.66	1.22 ± 0.54
-	4-OCH ₃	1.55 ± 0.37	1.61 ± 0.41	1.67 ± 0.48	1.95 ± 0.76
-	4-CH ₃	2.09 ± 0.82	2.10 ± 1.05	2.34 ± 1.12	2.44 ± 1.27
-	4-N(CH ₃) ₂	2.76 ± 1.55	2.38 ± 1.21	2.88 ± 1.89	3.17 ± 2.76
-	3,5-(CH ₃) ₂	3.16 ± 2.49	2.66 ± 1.44	2.81 ± 1.52	2.56 ± 1.33
Etoposide	-	2.11 ± 0.024	3.08 ± 0.135	0.13 ± 0.017	1.31 ± 0.27

Eight of the twelve synthesized compounds showed potent anticonvulsant activity through antagonism with pentylenetetrazole. This indicates that the compounds are potential candidates for the treatment of neurological disorders such as epilepsy. Furthermore, these compounds also exhibited anxiolytic effects, activating behaviors, and sedative properties, meaning that they could also be treatment options for such disorders. In particular, a fourfold increase in olfactory cell studies compared to diazepam was observed, further reinforcing the potential of these compounds for neurological treatment [82].

2.3 Antimicrobial activity studies

The study by Desai et al. in 2021 aimed to develop new pyridine-containing compounds 15 as potential antimicrobial agents (Figure 11).

These compounds were evaluated for both antibacterial and antifungal activities (Table 7). In particular, 3-OH and 4-F-linked compounds were found to exhibit good activity against *S. aureus* and *Escherichia coli* bacteria, respectively. It was also reported that the 2,4-dichloro-linked compound showed superior activity against *Pseudomonas aeruginosa* compared to the standard drugs ampicillin and chloramphenicol. This compound was also found to be highly effective against *Streptococci pyogenes*. In the study, it was emphasized that derivatives with electron-donating groups (2-OH, 3-OH, 4-CH₃, and 4-OH-3-OCH₃) showed both antibacterial and antifungal activity. In contrast, derivatives bearing electron-withdrawing groups (4-F and 2,4-dichloro) showed a marked increase in antibacterial activity. In terms of antifungal activities, 4-CH₃

and 4-OH-3-OCH₃-linked compounds exhibited significant activities against various fungal strains.




Figure 11. Synthesis of compound 15.

Table 7. Screening results in µg/mL for compounds showing potent antibacterial and antifungal activity and drugs used as standards.

Compound	R	Minimum bactericidal concentrations (MBC)				Minimum fungicidal concentrations (MFC)		
		<i>E. c.</i>	<i>P. a.</i>	<i>S. a.</i>	<i>S. p.</i>	<i>C. a.</i>	<i>A. n.</i>	<i>A. c.</i>
-	2-OH	250	500	100	125	500	50	>1000
-	3-OH	100	500	50	500	100	>1000	>1000
-	4-CH ₃	100	500	250	250	>1000	12.5	>1000
-	4-F	100	200	250	250	200	1000	500
-	2,4-(Cl) ₂	250	12.5	500	25	250	500	500
-	4-OH-3-OCH ₃	100	500	125	500	12.5	>1000	12.5
Ampicillin	-	100	100	250	100	-	-	-
Chloramphenicol	-	50	50	50	50	-	-	-
Nystatin	-	-	-	-	-	100	100	100
Griseofulvin	-	-	-	-	-	500	100	100

Abbreviation: *A. c.*, *Aspergillus clavatus*; *A. n.*, *Aspergillus niger*; *C. a.*, *Candida albicans*; *E. c.*, *Escherichia coli*; *P. a.*, *Pseudomonas aeruginosa*; *S. a.*, *Staphylococcus aureus*; *S. p.*, *Streptococcus pyogenes*.

It was reported that 4-CH₃-linked compounds showed significant antifungal activity against *Aspergillus niger*, and 4-OH-3-OCH₃-linked compounds exhibited excellent activity against *Candida albicans* and *Aspergillus clavatus* fungi. These results suggest that novel pyridine-containing compounds have potential as antimicrobial agents and may be effective against fungal infections [83].

The study by Borthakur et al. in 2020 focused on the synthesis of 1,3-thiazolopyrimidine derivatives 18 using 4-phenylthiazol-2-amine 16 and arylidinemalononitrile 17 (Figure 12).




Figure 12. Synthesis of compound 18.

The antifungal activities of the synthesized compounds were carried out by testing them against *Rhizoctonia solani* and *Drechslera oryzae*, two fungal pathogens causing diseases in rice crops. The results showed that four compounds exhibited mild to moderate antifungal activity (Table 8). This suggests that these compounds could be developed as a potential agricultural antifungal if further tested with other agriculturally important fungi. The study reveals that new antifungal agents can make an important contribution for disease control in agriculture [84].

In a study conducted by Hari et al. in 2022, 16 pyrimidine derivatives 19 were synthesized, and the antibacterial activity of these compounds was evaluated (Figure 13). Some of the synthesized compounds showed strong inhibition against bacteria such as *Xanthomonas campestris* pv. *Campestris*, *Pseudomonas fluorescens*, and *Bacillus subtilis*, while other compounds were moderately effective (Table 9). Such studies can be an important step towards the development of new antibacterial agents. Further research on the structural properties and antibacterial mechanisms of the target molecules will help to better understand the potential of these compounds [85].

In 2024, Elsayed et al. utilized the chalcone derivative 20, obtained from 4-bromoacetophenone and 3,4-

dimethoxybenzaldehyde, as the starting material for the synthesis of pyridine 21 and thienopyridine 22-23 compounds in their studies on the development of new antimicrobial agents. In the study, thienopyridine derivative was obtained from the reaction of chalcone with 2-cyanothioacetamide, and this intermediate product was converted into various pyridine and thienopyridine derivatives by one- or two-step reactions with 2-chloro-N-arylacetyl derivatives, α-haloketones, methyl iodide, and chloroacetonitrile (Figure 14). All synthesized compounds were evaluated against *E. coli*, *B. mycoides*, and *C. albicans*, and two compounds showed strong antimicrobial activity (Table 10). The findings suggest that these derivatives have antimicrobial potential and that the relationship between their structural properties and biological activities is important [86].




Figure 13. Synthesis of compound 19.




Figure 14. Synthesis of compound 20, 21, 22 and 23 compound.

Table 8. Results of inhibition percentages of compounds with antifungal activity and carbendazim used as standard.

Compound	Ar	<i>Rhizoctonia solani</i> Concentration		<i>Drechslea oryzae</i> Concentration	
		A.I. (50 ppm)	A.I. (100 ppm)	A.I. (50 ppm)	A.I. (100 ppm)
-	4-Cl-C ₆ H ₄	48.86	64.10	51.09	57.76
-	4-OH-3-OCH ₃ -C ₆ H ₃	37.87	65.88	43.25	55.78
-	4-N(CH ₃) ₂ -C ₆ H ₄	34.77	54.55	54.75	70.45
-	4-OCH ₃ -C ₆ H ₄	46.75	52.76	46.54	67.95
Carbendazim	-	96.67	98.56	95.45	98.26

Table 9. *In vitro* effects of compounds with potent antimicrobial activity and chloramphenicol used as a standard.

%Inhibition Compared to Positive Control				
Compound	R	<i>Xanthomonas campestris</i> pv. <i>Campestris</i>	<i>Pseudomonas fluorescens</i>	<i>Bacillus subtilis</i>
-	4-Br-C ₆ H ₄	63.90	70.61	51.02
-	3,5-(CH ₃) ₂ -C ₆ H ₃	65.76	71.33	51.39
-	4-Cl-C ₆ H ₄	67.12	69.89	57.49
-	2-NH ₂ -C ₆ H ₄	67.46	73.12	56.56
-	4-OCH ₃ -C ₆ H ₄	66.78	70.97	58.41
Chloramphenicol	-	100	100	100

Table 10. Antimicrobial activity evaluation of compounds by agar diffusion and MIC values.

Compound	R	Inhibition zone (mm)			MIC value (mg/mL)		
		<i>E. coli</i>	<i>B. mycoides</i>	<i>C. albicans</i>	<i>E. coli</i>	<i>B. mycoides</i>	<i>C. albicans</i>
22	COOEt	32	33	31	0.0195	>0.0048	>0.0048
23	-	28	28	29	> 0.0048	0.0098	0.039
Ampicillin 10 µg	-	20	12	14	-	-	-
Gentamicin 10 µg	-	12	11	12	-	-	-
Tobramycin 10 µg	-	13	10	12	-	-	-

3 Pyridine and pyrimidine derivative drugs

In recent years, nitrogen-containing fused heterocyclic compounds have attracted great interest in the field of drug discovery. In particular, pyridine and pyrimidine derivatives have become important building blocks in drug discovery, exhibiting a variety of pharmacological properties such as antiviral, antibacterial, antimicrobial and anticancer activities [87],[88]. Such a wide range of biological activity of these compounds is based on the strong interactions of the nitrogen atom in their chemical structure with biological systems. Nitrogen-containing heterocyclic compounds can interact with biological targets by forming hydrogen bonds with biomolecules or by altering electron density. These interactions make them effective against biological agents such as viruses, bacteria and cancer cells. Therefore, pyridine and pyrimidine derivatives stand out as potential drug candidates for the treatment of various diseases and play a critical role in drug development processes [89]-[92]. The pharmacological potentials of pyridine and pyrimidine-containing drugs, which prove their broad efficacy, and the structure of marketed drugs such as minoxidil, divaplon, indiplon, trimethoprim, ocinaplon, etc. are shown below (Table 11).

4 Conclusions

This review systematically brings together the recent synthetic strategies and reported biological activities of pyridine- and pyrimidine-based heterocycles. By outlining both the diversity of synthetic methodologies and the wide spectrum of

pharmacological evaluations, we provide a comprehensive perspective that allows researchers to better link chemical design with biological potential. The survey of literature reveals not only the versatility of these scaffolds but also the recurring emphasis on their anticancer, antimicrobial, and neurotropic properties, which highlights promising directions for drug discovery. While our work does not aim to cover mechanistic details exhaustively, its contribution lies in integrating chemical and biological knowledge into a single framework, thus serving as a useful reference point for medicinal chemists. We believe that this synthesis of information can facilitate a more rational approach to the exploration of nitrogen-containing heterocycles and stimulate further innovation in the field.

5 Author contribution statements

Gönül Bükülmez, contributed to the conception of the idea, literature review, writing, and editing of the article, and Rahmi Kasımoğulları, contributed to the literature review and editing of the article.

6 Ethics committee approval and conflict of interest statement

"The prepared article does not require approval from the ethics committee".

"The article was written with no conflict of interest with any individual or organization".

Table 11. Marketed drugs containing pyridines and pyrimidines.












S. No	Drug	Structure	Treatment	Ref.
1	Minoxidil		Vasodilator	[93]
2	Divaplon		Anticonvulsant and anxiolytic	[94]
3	Indiplon		Sedative-hypnotic	[95]
4	Trimethoprim		Antibiotic	[96]
5	Ocinaplon		Anxiolytic	[97]
6	Etravirine		Antiviral	[98]
7	Stavudine		Anti-HIV	[99]
8	Isoniazid		Antituberculosis	[100]
9	Levofloxacin		Anti-allergic	[101]

Table 11. Continued.

S. No	Drug	Structure	Treatment	Ref.
10	Iclaprim		Antibiotic	[102]
11	Trilaciclib		Small-cell lung cancer	[103]
12	Ribociclib		Breast cancer	[104]
13	Palbociclib		Advanced cancer	[105]
14	Vonoprazan		Gastroesophageal reflux and peptic ulcer	[106]
15	Futibatinib		Non-small cell lung cancer and breast cancer	[107]
16	Olutasidenib		Acute myeloid leukaemia	[108]
17	Omidenepag		Glaucoma and ocular hypertension	[109]

Table 11. Continued.

S. No	Drug	Structure	Treatment	Ref.
18	Flucytosine		Antifungal	[110]
19	Tisopurine		Disorders associated with hyperuricemia	[111]
21	Piribedil		Parkinsonism	[112]

7 References

- [1] Wang S, Bao L, Song D, Wang J, Cao X. "Heterocyclic lactam derivatives containing piperonyl moiety as potential antifungal agents". *Bioorganic & Medicinal Chemistry Letters*, 29(20), 126661, 2019.
- [2] Korol N, Molnar-Babilya D, Slivka M, Onysko M. "A brief review on heterocyclic compounds with promising antifungal activity against *Candida* species". *Organic Communications*, 15(4), 304-323, 2022.
- [3] Muslim RF, Owaid MN. "Synthesis, characterization and evaluation of the anti-cancer activity of silver nanoparticles by natural organic compounds extracted from *Cyperus* sp. rhizomes". *ACTA Pharmaceutica Scientia*, 57(2), 129, 2019.
- [4] Yang L, Bo Xu W, Sun L, Zhang, C, Hua Jin C. "SAR analysis of heterocyclic compounds with monocyclic and bicyclic structures as antifungal agents". *ChemMedChem*, 17(12) e202200221, 2022.
- [5] Mermer A, Keles, T, Sirin Y. "Recent studies of nitrogen containing heterocyclic compounds as novel antiviral agents: A review". *Bioorganic Chemistry*, 114, 105076, 2021.
- [6] Negi M, Chawla PA, Faruk A, Chawla V. "Role of heterocyclic compounds in SARS and SARS CoV-2 pandemic". *Bioorganic Chemistry*, 104, 104315, 2020.
- [7] Borchers, A, Pieler, T. "Programming pluripotent precursor cells derived from *Xenopus* embryos to generate specific tissues and organs". *Genes (Basel)*, 1(3), 413-26, 2010.
- [8] Wang SB, Liu H, Li GY, Li J, Li XJ, Lei K, Liu RM. "Coumarin and 3,4-dihydroquinolinone derivatives: Synthesis, antidepressant activity, and molecular docking studies". *Pharmacological Reports*, 71(6), 1244-1252, 2019.
- [9] Kim JY, Kim D, Kang SY, Park WK, Kim HJ, Jung ME, Lee J. "Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant". *Bioorganic & Medicinal Chemistry Letters* 20(22), 6439-42, 2010.
- [10] Singh K, Pal R, Khan SA, Kumar B, Akhtar MJ. "Insights into the structure activity relationship of nitrogen-containing heterocyclics for the development of antidepressant compounds: An updated review". *Journal of Molecular Structure*, 1237, 130369, 2021.
- [11] Akhtar J, Khan, AA, Ali Z, Haider R, Yar MS. "Structure-activity relationship (SAR) study and design strategies of nitrogen-containing heterocyclic moieties for their anticancer activities". *European Journal of Medicinal Chemistry*, 125, 143-189, 2017.
- [12] Mirza AZ. "Advancement in the development of heterocyclic nucleosides for the treatment of cancer-a review". *Nucleosides Nucleotides Nucleic Acids*, 38(11), 836-857, 2019.
- [13] Sharma S, Kumar D, Singh G, Monga V, Kumar B. "Recent advancements in the development of heterocyclic anti-inflammatory agents". *European Journal of Medicinal Chemistry*, 200, 112438, 2020.
- [14] Wei ZY, Chi KQ, Wang KS, Wu J, Liu LP, Piao HR "Design, synthesis, evaluation, and molecular docking of ursolic acid derivatives containing a nitrogen heterocycle as anti-inflammatory agents". *Bioorganic & Medicinal Chemistry Letters*, 28(10), 1797-1803, 2018.
- [15] Abubakar S, Khairuddean M, Ismail N Z, Salhimi SM, Al-Amin M, Wahyuningsih TD. "Synthesis and computational insights of hybrid heterocyclic bis-chalcone compounds and their cytotoxic effects against breast cancer cells". *Results in Chemistry*, 7, 101464, 2024.
- [16] Albratty M, Alhazm HA. "Novel pyridine and pyrimidine derivatives as promising anticancer agents: A review". *Arabian Journal of Chemistry*, 15(6), 103846, 2022.
- [17] Borah B, Banerjee S, Allam BK "Recent Advances in the Catalytic Applications of Tin Dioxide-Based Materials in the Synthesis of Bioactive Heterocyclic Compounds". *Tetrahedron Green Chem*, 4, 100048, 2024.
- [18] Macit AZ, Hasanoğlu Özkan E, Ogutcu H, Nartop D. "Nartop, synthesis and *in vitro* antimicrobial evaluation of novel potent bioactive heterocyclic compounds". *Polycyclic Aromatic Compounds*, 44(10), 6862-6873, 2024.

- [19] Masaret, GS. "New Potential Antitumor Pyrimidine Derivatives: Synthesis and Cytotoxicity Evaluation". *Polycyclic Aromatic Compounds*, 42(8), 5336-5351, 2022.
- [20] Savcı A, Turan N, Buldurun K, Alkış M E, Alan Y. "Schiff base containing fluorouracil and its M (II) complexes: Synthesis, characterization, cytotoxic and antioxidant activities". *Inorganic Chemistry Communications*, 143, 109780, 2022.
- [21] Savcı A, Buldurun K, Kirkpantur G. "A new Schiff base containing 5-FU and its metal Complexes: Synthesis, Characterization, and biological activities". *Inorganic Chemistry Communications*, 134, 109060, 2021.
- [22] Buldurun K, Turan N, Aras A, Mantarcı A, Turkan F, Bursal E. "Spectroscopic and structural characterization, enzyme inhibitions, and antioxidant effects of new Ru (II) and Ni (II) complexes of Schiff base". *Chemistry & biodiversity*, 16(8), e1900243, 2019.
- [23] Buldurun K, Turan N, Savcı A, Alan Y, Colak N. "Synthesis, characterization, X-ray diffraction analysis of a tridentate Schiff base ligand and its complexes with Co (II), Fe (II), Pd (II) and Ru (II): Bioactivity studies". *Iran. J. Chem. Chem. Eng. Research*, 41(8), 2635-2649, 2022.
- [24] Ibarra-Rodríguez M, Muñoz-Flores B M, Dias H R, Sanchez M, Gomez-Trevino A, Santillan R, Farfán N, Jimenez-Perez VM. "Fluorescent molecular rotors of organoboron compounds from schiff bases: synthesis, viscosity, reversible thermochromism, cytotoxicity, and bioimaging cells". *The Journal of Organic Chemistry*, 82(5), 2375-2385, 2017.
- [25] Goshisht M K, Patra G K, Tripathi N. "Fluorescent Schiff base sensors as a versatile tool for metal ion detection: strategies, mechanistic insights, and applications". *Materials Advances*, 3(6), 2612-2669, 2022.
- [26] Kagatkar S, Sunil D. "Schiff bases and their complexes in organic light emitting diode application". *Journal of Electronic Materials*, 50(12), 6708-6723, 2021.
- [27] Buldurun K, Tanış E, Turan N, Çolak N, Çankaya N. "Solvent effects on the electronic and optical properties of Ni (II), Zn (II), and Fe (II) complexes of a Schiff base derived from 5-bromo-2-hydroxybenzaldehyde". *Journal of Chemical Research*, 45(7-8), 753-759, 2021.
- [28] Jeevasan AW, Murugavel KK, Neelakantan M A. "Review on Schiff bases and their metal complexes as organic photovoltaic materials". *Renewable and Sustainable Energy Reviews*, 36, 220-227, 2014.
- [29] El-Remaily MAEAAA, El-Dabea T, El-Khatib RM, Abdou A, El Hamd MA, Abu-Dief AM. "Efficiency and development of guanidine chelate catalysts for rapid and green synthesis of 7-amino-4, 5-dihydro-tetrazolo [1,5-*a*] pyrimidine-6-carbonitrile derivatives supported by density functional theory (DFT) studies". *Applied Organometallic Chemistry*, 37(11), e7262, 2023.
- [30] HM P, Khanum SA "An Overview of the Synthetic Routes and Pharmacological Aspects of Pyridine, Isoxazole, Thiazole, and Indole Derivatives". *Polycyclic Aromatic Compounds*, 44(10), 7168-7196, 2023.
- [31] Abdel-Megeed MF, Badr BE, Azaam M M, El-Hiti G A. "Synthesis, antimicrobial and anticancer activities of a novel series of diphenyl 1-(pyridin-3-yl)ethylphosphonates". *Bioorganic & Medicinal Chemistry*, 20(7), 2252-2258, 2012.
- [32] Shukla NM, Salunke DB, Yoo E, Mutz CA, Balakrishna R, David SA. "Antibacterial activities of Groebke-Blackburn-Bienayme-derived imidazo[1,2-*a*]pyridin-3-amines". *Bioorganic & Medicinal Chemistry*, 20(19), 5850-5863, 2012.
- [33] Jardosh HH, Patel MP "Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents". *European Journal of Medicinal Chemistry*, 65, 348-359, 2013.
- [34] Kim HS, Jadhav JR, Jung SJ, Kwak JH. "Synthesis and antimicrobial activity of imidazole and pyridine appended cholestane-based conjugates". *Bioorganic & Medicinal Chemistry Letters*, 23(15), 4315-4318, 2013.
- [35] Jose G, Suresha Kumara, TH Nagendrappa G, Sowmya HB, Jasinski JP, Millikan SP, Chandrika N, More SS, Harish BG. "New polyfunctional imidazo[4,5-*c*]pyridine motifs: synthesis, crystal studies, docking studies and antimicrobial evaluation". *European Journal of Medicinal Chemistry*, 77, 288-97, 2014.
- [36] Jose G, Suresha Kumara TH, Nagendrappa G, Sowmya HBV, Jasinski JP, Millikan SP, More SS, Janardhan B, Harish BG, Chandrika N. "Synthesis, crystal structure, molecular docking and antimicrobial evaluation of new pyrrolo[3,2-*c*]pyridine derivatives". *Journal of Molecular Structure*, 1081, 85-95, 2015.
- [37] Kumar S, Sharma N, Maurya I K, Bhasin AKK, Wangoo N, Brandao P, Felix V, Bhasin KK, Sharma RK. "Facile synthesis, structural evaluation, antimicrobial activity and synergistic effects of novel imidazo[1,2-*a*]pyridine based organoselenium compounds". *European Journal of Medicinal Chemistry*, 123, 916-924, 2016.
- [38] El-Gohary NS, Gabr MT, Shaaban MI. "Synthesis, molecular modeling and biological evaluation of new pyrazolo[3,4-*b*]pyridine analogs as potential antimicrobial, antiquorum-sensing and anticancer agents". *Bioorganic Chemistry*, 89, 102976, 2019.
- [39] Azzam RA, Elsayed RE, Elgemei GH. "Design and Synthesis of a New Class of Pyridine-Based N-Sulfonamides Exhibiting Antiviral, Antimicrobial, and Enzyme Inhibition Characteristics". *ACS Omega*, 5(40), 26182-26194, 2020.
- [40] Milosevic MD, Marinkovic AD, Petrovic P, Klaus A, Nikolic MG, Prlainovic NZ, Cvijetic IN. "Synthesis, characterization and SAR studies of bis(imino)pyridines as antioxidants, acetylcholinesterase inhibitors and antimicrobial agents". *Bioorganic Chemistry*, 102, 104073, 2020.
- [41] Kamat V, Santosh R, Poojary B, Nayak SP, Kumar BK, Sankaranarayanan M, Faheem Khanapure S, Barretto DA, Vootla SK. "Pyridine- and Thiazole-Based Hydrazides with Promising Anti-inflammatory and Antimicrobial Activities along with Their In Silico Studies". *ACS Omega*, 5(39), 25228-25239, 2020.
- [42] Ali I, Burki S, El-Haj B M, Shafiullah Parveen S, Nadeem HS, Nadeem S, Shah MR. "Synthesis and characterization of pyridine-based organic salts: Their antibacterial, antibiofilm and wound healing activities". *Bioorganic Chemistry*, 100, 103937, 2020.
- [43] Radwan MAA, Alshubramy MA, Abdel-Motaal M, Hemdan BA, El-Kady DS. "Synthesis, molecular docking and antimicrobial activity of new fused pyrimidine and pyridine derivatives". *Bioorganic Chemistry*, 96, 103516, 2020.

- [44] Mamedov I, Naghiyev F, Maharramov A, Uwanguo O, Farewell A, Sunnerhagen P, Erdelyi M. "Antibacterial activity of 2-amino-3-cyanopyridine derivatives". *Mendeleev Communications*, 30(4), 498-499, 2020.
- [45] Gangjee A, Namjoshi OA, Yu J, Ihnat MA, Thorpe JE, Bailey-Downs L C. N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and *in vivo* evaluation as antiangiogenic, antimetastatic and antitumor agents". *Bioorganic & Medicinal Chemistry*, 21(5), 1312-23, 2013.
- [46] Chand K, Prasad S, Tiwari R K, Shirazi AN, Kumar S, Parang K, Sharma S K. "Synthesis and evaluation of c-Src kinase inhibitory activity of pyridin-2(1H)-one derivatives". *Bioorganic Chemistry*, 53, 75-82, 2014.
- [47] Hu H, Wu J, Ao M, Zhou X, Li B, Cui Z, Wu T, Wang L, Xue, Y, Wu Z, Fang M. "Design, synthesis and biological evaluation of methylenehydrazine-1-carboxamide derivatives with [5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole scaffold: Novel potential CDK9 inhibitors". *Bioorganic Chemistry*, 102, 104064, 2020.
- [48] Yang H, Li Q, Su M, Luo F, Liu Y, Wang D, Fan Y. "Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition". *Bioorganic & Medicinal Chemistry*, 46, 116346, 2021.
- [49] Ye Q, Fu C, Li J. "Studying the Binding Modes of Novel 2-Aminopyridine Derivatives as Effective and Selective c-Met Kinase Type 1 Inhibitors Using Molecular Modeling Approaches". *Molecules*, 26(52), 1-18, 2020.
- [50] Miranda PO, Cubitt B, Jacob N T, Janda K D, de la Torre, J C "Mining a Krohnke Pyridine Library for Anti-Arenavirus Activity". *ACS Infectious Diseases*, 4(5), 815-824, 2018.
- [51] Wang G, Wan J, Hu Y, Wu X, Prhavc M, Dyatkina N, Rajwanshi V K, Smith D B, Jekle A, Kinkade A, Symons J A, Jin Z, Deval J, Zhang Q, Tam Y, Chanda S, Blatt L, Beigelman L. "Synthesis and Anti-Influenza Activity of Pyridine, Pyridazine, and Pyrimidine C-Nucleosides as Favipiravir (T-705) Analogues". *Journal of Medicinal Chemistry*, 59(10), 4611-24, 2016.
- [52] de Candia M, Fiorella F, Lopopolo G, Carotti A, Romano M R, Lograno M D, Martel S, Carrupt P A, Belviso BD, Caliendo R, Altomare C. "Synthesis and biological evaluation of direct thrombin inhibitors bearing 4-(piperidin-1-yl)pyridine at the P1 position with potent anticoagulant activity". *Journal of Medicinal Chemistry*, 56(21), 8696-711, 2013.
- [53] Kang S, Kim RY, Seo MJ, Lee S, Kim YM, Seo M, Seo JJ, Ko Y, Choi I, Jang J, Nam J, Park S, Kang H, Kim HJ, Kim J, Ahn S, Pethe K, Nam K, No Z, Kim J. "Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent". *Journal of Medicinal Chemistry*, 57(12), 5293-305, 2014.
- [54] Tantry S J, Markad SD, Shinde V, Bhat J, Balakrishnan G, Gupta, AK, Ambady A, Raichurkar A, Kedari C, Sharma S, Mudugal NV, Narayan A, Naveen Kumar CN. Nanduri R, Bharath S, Reddy J, Panduga V, Prabhakar K R, Kandaswamy K, Saralaya R, Kaur P, Dinesh N, Gupta S, Rich K, Murray D, Plant H, Ashton H, Plant D, Walsh J, Alcock P, Naylor K, Collier M, Whiteaker J, McLaughlin R E, Mallya M, Panda M, Rudrapatna S, Ramachandran V, Shandil R, Sambandamurthy VK, Mdluli K, Cooper CB, Rubin H, Yano T, Iyer P, Narayanan S, Kavanagh S, Mukherjee K, Balasubramanian V, Hosagrahara VP, Solapure S, Ravishankar S, & Hameed P S. "Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis". *Journal of Medicinal Chemistry*, 60(4), 1379-1399, 2017.
- [55] Sagar SR, Singh D P, Das R D, Panchal NB, Sudarsanam V, Nivsarkar M, Vasu KK "Investigations on substituted (2-aminothiazol-5-yl)(imidazo[1,2-a]pyridin-3-yl)methanones for the treatment of Alzheimer's disease". *Bioorganic & Medicinal Chemistry*, 36, 116091, 2021.
- [56] Zarei S, Shafiei M, Firouzi M, Firoozpour L, Divsalar K, Asadipour A, Akbarzadeh T, Foroumadi A. "Design, synthesis and biological assessment of new 1-benzyl-4-((4-oxoquinazolin-3(4H)-yl)methyl) pyridin-1-ium derivatives (BOPs) as potential dual inhibitors of acetylcholinesterase and butyrylcholinesterase". *Heliyon*, 7(4), e06683, 2021.
- [57] Chiacchio MA, Iannazzo D, Romeo R, Giofrè SV, Legnani L. "Pyridine and pyrimidine derivatives as privileged scaffolds in biologically active agents" *Current Medicinal Chemistry*, 26(40), 7166-7195, 2019.
- [58] Lackey HH, Chen Z, Harris JM, Peterson EM, Heemstra JM. "Single-molecule kinetics show DNA pyrimidine content strongly affects RNA: DNA and TNA: DNA heteroduplex dissociation rates". *ACS Synthetic Biology*, 9(2), 249-253, 2020.
- [59] Martina M G, Giannessi L, Radi M. "Multicomponent Synthesis of Purines and Pyrimidines: From the Origin of Life to New Sustainable Approaches for Drug-Discovery Applications". *European Journal of Organic Chemistry*, 26(2), e202201288, 2022.
- [60] Nassar E, El Badry YA, Eltoukhy A M M "Synthesis and antiproliferative activity of 1-(4-(1H-Indol-3-Yl)-6-(4-Methoxyphenyl)Pyrimidin-2-yl)Hydrazine and its pyrazolo pyrimidine derivatives". *Medicinal Chemistry*, 06(04), 2016.
- [61] Kamal A, Reddy J S, Ramaiah MJ, Dastagiri D, Bharathi EV, Prem Sagar MV, Pushpavalli S N C V L, Ray P, Pal-Bhadra M. "Design, synthesis and biological evaluation of imidazopyridine/pyrimidine-chalcone derivatives as potential anticancer agents". *Medicinal Chemistry Communications*, 1(5), 355, 2010.
- [62] Mathew B, Suresh J, Anbazhagan S, Paulraj J, Krishnan GK. Krishnan "Heteroaryl chalcones: Mini review about their therapeutic voyage". *Biomedicine & Preventive Nutrition*, 4(3), 451-458, 2014.
- [63] Brown KK, Spinelli JB, Asara JM, Toker A. "Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer". *Cancer Discovery*, 7(4), 391-399, 2017.
- [64] Hassan, A S, Mady, M F, Awad, H M, Hafez, T S. "Synthesis and antitumor activity of some new pyrazolo[1,5-a]pyrimidines". *Chinese Chemical Letters*, 28(2), 388-393, 2017.
- [65] Khalaf HS, Tolan HEM, Radwan MAA, Mohamed AM, Awad HM, El-Sayed W A. "Design, synthesis and anticancer activity of novel pyrimidine and pyrimidine-thiadiazole hybrid glycosides". *Nucleosides Nucleotides Nucleic Acids*, 39(7), 1036-1056, 2020.

- [66] Banda V, Jitender DG, Santhosh K G, Sambasiva RP, Chavva K, Rajesh P, Venkateswara RJ, Banda N. "Studies on Synthesis of Novel Pyrido[2,3-*d*] pyrimidine Derivatives and Their Anticancer Activity". *Journal of Heterocyclic Chemistry*, 55(11), 2538-2544, 2018.
- [67] Padarathi P K, Sridhar S, Jagatheesh K, Namasivayam E. "Synthesis and Biological Activity of Imidazole Derived Chalcones and It's Pyrimidines". *International journal of Research in Ayurveda & Pharmacy*, 4(3), 355-362, 2013.
- [68] Hassan MM, Farouk O. "Synthesis and antimicrobial evaluation of some functionalized heterocycles derived from novel quinolinyl chalcone". *Journal of Heterocyclic Chemistry*, 54(6), 3133-3142, 2017.
- [69] Gaikwad SS, Suryawanshi VS, Lohar KS, Jadhav DV, Shinde ND. "Synthesis and biological activity of some 3,4-Dihydro-4-(4-substituted aryl)-6-(naphtho[2,1-*b*]furan-2-yl) pyrimidine-2(1*H*)-one Derivatives". *Journal of Chemistry*, 9(1), 175-180, 2011.
- [70] Hussein AHM, Gad-Elkareem MAM, El-Adasy A.-BAAM, Khames AA, Othman I.M.M. "β-Oxoanilides in heterocyclic synthesis: synthesis and antimicrobial activity of pyridines, pyrans, pyrimidines and azolo, azinopyrimidines incorporating antipyrine moiety". *International Journal of Organic Chemistry*, 2(04), 341-351, 2012.
- [71] Anupama B. Singh "Synthesis of pharmacologically important some novel pyrimidine and chalcone moieties containing s-triazines". *American Chemical Science Journal*, 8(2), 1-7, 2015.
- [72] Perlikova P, Hocek M. "Pyrrolo[2,3-*d*]pyrimidine (7-deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides". *Medicinal Research Reviews*, 37(6), 1429-1460, 2017.
- [73] Shen J, Meng X. "Selective synthesis of pyrimidines from cinnamyl alcohols and amidines using the heterogeneous OMS-2 catalyst". *Catalysis Communications*, 138, 105846, 2020.
- [74] Radwan M A, Alshubramy M A, Abdel-Motaal M, Hemdan BA, El-Kady DS. "Synthesis, molecular docking and antimicrobial activity of new fused pyrimidine and pyridine derivatives". *Bioorganic Chemistry*, 96, 103516, 2020.
- [75] Jian X E, Yang F, Jiang CS, You W W, Zhao PL. "Synthesis and biological evaluation of novel pyrazolo[3,4-*b*]pyridines as cis-restricted combretastatin A-4 analogues". *Bioorganic & Medicinal Chemistry Letters*, 30(8), 127025, 2020.
- [76] Hatti I, Sujana O, Nookaraju M, Suresh J, Aparna Seetharam K, Raju R R. "Rational design, synthesis, and anticancer evaluation of pyridine and substituted aryl linked 1,3,4-oxadiazole derivatives". *Results in Chemistry*, 11, 101755, 2024.
- [77] Jami PK, Battula S R, Sandhya J, Parimi UD. "Design, synthesis and biological evaluation of amide derivatives of isoxazole-imidazo[1,2-*a*]pyridine as anticancer agents". *Chemical Data Collections*, 44, 101001, 2023.
- [78] Zhang J, Dai J, Lan X, Zhao Y, Yang F, Zhang H, Tang S, Liang G, Wang X, Tang Q. "Synthesis, bioevaluation and molecular dynamics of pyrrolo-pyridine benzamide derivatives as potential antitumor agents *in vitro* and *in vivo*". *European Journal of Medicinal Chemistry*, 233, 114215, 2022.
- [79] Khan S, Ullah H, Rahim F, Hussain R, Khan Y, Khan MS, Iqbal R, Ali B, Albeshr MF. "Synthesis, biological evaluation and molecular docking study of pyrimidine based thiazolidinone derivatives as potential anti-urease and anti-cancer agents". *Journal of Saudi Chemical Society*, 27(4), 101688, 2023.
- [80] Wang S, Zhang RH, Zhang H, Wang YC, Yang D, Zhao YL, Yan G Y, Xu G B, Guan HY, Zhou YH, Cui DB, Liu T, Li YJ, Liao SG, Zhou M. "Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities". *European Journal of Medicinal Chemistry*, 222, 113573, 2021.
- [81] Reddy BS, Rao GPC, Devi ER, Prasad KRS, Nalla S. "Synthesis and biological evaluation of 1,2,3-triazole incorporated pyridin-4-yl)-1*H*-1,2,4-triazol-3-yl)pyrimidine derivatives as anticancer agents". *Results in Chemistry*, 8, 101598, 2024.
- [82] Dashyan SS, Babaev E V, Ayvazyan AG, Mamyan SS, Paronikyan EG, Nikoghosyan TA, Hunanyan L S, Paronikyan R G. "Synthesis, evaluation of biological activity and SAR of new thioalkyl derivatives of pyridine". *Bioorganic Chemistry*, 148, 107435, 2024.
- [83] Desai NC, Vaja DV, Monapara JD, Manga V, Vani T. "Synthesis, biological evaluation, and molecular docking studies of novel pyrazole, pyrazoline-clubbed pyridine as potential antimicrobial agents". *Journal of Heterocyclic Chemistry*, 58(3), 737-750, 2021.
- [84] Borthakur SK, Kalita PK, Borthakur S. "Synthesis and antifungal activities of 3,5-diphenyl-7-amino-[1,3]-thiazolo[3,2-*a*]pyrimidine-6-nitrile derivatives". *Journal of Heterocyclic Chemistry*, 57(3), 1261-1265, 2020.
- [85] Hari KN, Poojary B, Chandrasehar G. "Design, synthesis and evaluation of new alkylated pyrimidine derivatives as antibacterial agents". *Results in Chemistry*, 4, 100676, 2022.
- [86] Elsayed MA, Elsayed AM, Sroor FM. "Novel biologically active pyridine derivatives: Synthesis, structure characterization, *in vitro* antimicrobial evaluation and structure-activity relationship". *Medicinal Chemistry Research*, 33(3), 476-491, 2024.
- [87] Nerkar AU. "Use of Pyrimidine and Its Derivative in Pharmaceuticals: A Review". *Journal of Advanced Chemical Sciences*, 7(2), 729-732, 2021.
- [88] Roopan SM, Sompalle R. "Synthetic chemistry of pyrimidines and fused pyrimidines: A review". *Synthetic Communications*, 46(8), 645-672, 2016.
- [89] Kerru N, Gummidi L, Maddila S, Gangu KK, Jonnalagadda SB "A Review on Recent Advances in Nitrogen-Containing Molecules and Their Biological Applications". *Molecules*, 25(8), 2020.
- [90] Pinheiro S, Pinheiro EMC, Muri EMF, Pessôa J C, Cadorini MA, Greco SJ. "Biological activities of [1,2,4]triazolo[1,5-*a*]pyrimidines and analogs". *Medicinal Chemistry Research*, 29(10), 1751-1776, 2020.
- [91] Dai XJ, Xue LP, Ji SK, Zhou Y, Gao Y, Zheng YC, Liu HM, Liu HM. "Triazole-fused pyrimidines in target-based anticancer drug discovery". *European Journal of Medicinal Chemistry*, 249, 115101, 2023.
- [92] Oukoloff K, Lucero B, Francisco KR, Brunden K R, Ballatore C. "1,2,4-Triazolo[1,5-*a*]pyrimidines in drug design". *European Journal of Medicinal Chemistry*, 165, 332-346, 2019.

- [93] Frydrych A, Jurowski K. "Toxicity of minoxidil-Comprehensive in silico prediction of main toxicity endpoints: Acute toxicity, irritation of skin and eye, genetic toxicity, health effect, cardiotoxicity and endocrine system disruption". *Chemico-Biological Interactions*, 393, 110951, 2024.
- [94] Mohammed SM, Masry AA, Moustafa AH, El-Sayed HA, Gad EM, Morsy HA. "K₂CO₃-nanoparticles catalyzed the synthesis of 3-arylidine imidazo[1,2-c]pyrimidine candidates" Cytotoxic activity and docking study". *Synthetic Communications*, 53(16), 1319-1332, 2023.
- [95] Burgos CF, Sanchez C, Sepulveda C, Fuentes E, Palomo I, Alarcon M. "Anti-aggregation effect on platelets of Indiplon a hypnotic sedative non-benzodiazepine drug". *Biomed Pharmacother*, 111, 378-385, 2019.
- [96] Piccirillo G, Aroso R, Baptista JA, Silva GJ, Pereira MM, Canotilho J, Ermelinda SEM. "Trimethoprim-Based multicomponent solid Systems: Mechanochemical Screening, characterization and antibacterial activity assessment". *International Journal of Pharmaceutics*, 661, 124416, 2024.
- [97] Skolnick P. "Anxiolytic drugs: on a quest for the Holy Grail" *Trends in Pharmacological Sciences*, 33(11), 611-20, 2012.
- [98] Oktay AN, Polli JE. "Comparison of a single pharmaceutical surfactant versus intestinal biorelevant media for etravirine dissolution: Role and impact of micelle diffusivity". *International Journal of Pharmaceutics*, 624, 122015, 2022.
- [99] Muftakhov MV, Shchukin PV, Khatymov R V. "Thymidine and stavudine molecules in reactions with low-energy electrons". *Radiation Physics and Chemistry*, 184, 109464, 2021.
- [100] Bachir M, Guglielmetti L, Tunesi S, Billard-Pomares T, Chiesi S, Jaffre J, Langris H, Pourcher V, Schramm F, Lemaitre N, Robert J. "Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France". *Journal of Infection*, 85(1), 24-30, 2022.
- [101] Wang X, Cheng G, Liang X, Yang J, Deng A, Chen D, Liu C, Gao Y, Li J. "Toxic Epidermal Necrolysis Observed in a Patient With the HLA-B*1502 Treated With Levofloxacin". *Clinical Therapeutics*, 46(12), 1082-1085, 2024.
- [102] Neuner S, Gelbrich T, Wurst K, Spreitz J, Nerdinger S, Griesser UJ, Stefinovic M, Schottenberger H. "Iclaprim mesylate displaying a hydrogen-bonded molecular tape". *Acta Crystallographica Section E Crystallographic Communications*, 79(1), 24-27, 2023.
- [103] Hoseyni K, Sepehri B, Irani M. "Discovery of new Glyoxalase I inhibitors by repurposing of FDA-approved drugs: An in silico study". *Journal of Molecular Structure*, 1312, 138522, 2024.
- [104] Fiste O, Mavrothalassitis E, Apostolidou K, Trika C, Lontos M, Koutsoukos K, Kaparelou M, Dimitrakakis C, Gavriatopoulou MA, Dimopoulos MA, Zagouri F "Cardiovascular complications of ribociclib in breast cancer patients". *Critical Reviews in Oncology/Hematology*, 196, 104296, 2024.
- [105] Sedrak MS, Lee MK, Ji J, Satele DV, Freedman RA, Poorvu PD, O'Connor T, Williams GR, Hopkins JO, Muss HB, Cohen HJ, Partridge AH, Carey LA, Chow SL, Subbiah N, Le-Rademacher A, Jatoi A. "Palbociclib in adults aged 70 years and older with advanced breast cancer: A phase 2 multicenter trial (Alliance A171601)". *Journal of Geriatric Oncology*, 15(6), 101813, 2024.
- [106] Sakaguchi K, Naito T, Hoshikawa K, Miyadera Y, Tanaka H, Nakatsugawa E, Furuta T, Sugimoto K, Kawakami J. "Characterization of plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders". *Drug Metabolism and Pharmacokinetics*, 58, 101027, 2024.
- [107] Alzhrani RM, Almalki AH, Alosaimi ME, Algarni MA, Abduljabbar MH, Aldawsari MF, Alturki MS, Alsulami FT, Abdelazim AH "Spectrofluorometric determination of futibatinib in human plasma and pharmaceutical formulations". *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, 320, 124543, 2024.
- [108] Nehra B, Kumar M, Singh S, Chawla PA. "Olutasidenib: A ray of hope in the treatment of acute myeloid leukaemia". *Health Sciences Review*, 7, 100100, 2023.
- [109] Bacharach J, Brubaker JW, Evans DG, Lu F, Odani-Kawabata N, Yamabe T, Wirta DL. "Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)". *American Journal of Ophthalmology*, 263, 23-34, 2024.
- [110] Mashau R C, Meiring S T, Quan VC, Nel J, Greene G S, Garcia A, Menezes C, Reddy D L, Venter M, Stacey S, Madua, M, Boretti L, Harrison TS, Meintjes G, Shroufi A, Trivino-Duran L, Black J, Govender N P. "Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study". *Lancet Infect Dis*, 22(9), 1365-1373, 2022.
- [111] Zarenezhad E, Farjam M, Iraj A. "Synthesis and biological activity of pyrimidines-containing hybrids: Focusing on pharmacological application" *Journal of Molecular Structure* 1230, 129833, 2021.
- [112] Uppuluri CT, Ravi PR, Dalvi AV. "Design and evaluation of thermo-responsive nasal in situ gelling system dispersed with piribedil loaded lecithin-chitosan hybrid nanoparticles for improved brain availability". *Neuropharmacology*, 201, 108832, 2021.